Murphy SJX, et al. - Given the risk of vascular events among patients with carotid stenosis despite antiplatelet therapy, researchers comprehensively collated data on prescribed antiplatelet regimens from trials to guide optimal therapy in this population. They conducted this review in line with the current PRISMA statement and identified 25 relevant studies for inclusion. One randomized controlled trial supported no significant benefit of providing aspirin vs placebo for the treatment of asymptomatic carotid stenosis. However, peri-procedural treatment of asymptomatic and symptomatic patients with 81–325 mg of aspirin daily was supported by data from endovascular treatment trials. In patients with ≥ 50% symptomatic carotid stenosis, short-term aspirin–dipyridamole or aspirin–clopidogrel treatments seemed equally effective at reducing micro-embolic signals on transcranial Doppler ultrasound. Overall, this study yielded insufficient evidence recommending routine aspirin–clopidogrel combination therapy to annihilate the risk of recurrent clinical ischemic events in patients with symptomatic moderate–severe carotid stenosis.